AU2016336351A1 - Rational combination therapy for the treatment of cancer - Google Patents

Rational combination therapy for the treatment of cancer Download PDF

Info

Publication number
AU2016336351A1
AU2016336351A1 AU2016336351A AU2016336351A AU2016336351A1 AU 2016336351 A1 AU2016336351 A1 AU 2016336351A1 AU 2016336351 A AU2016336351 A AU 2016336351A AU 2016336351 A AU2016336351 A AU 2016336351A AU 2016336351 A1 AU2016336351 A1 AU 2016336351A1
Authority
AU
Australia
Prior art keywords
cancer
hsp90
pct
rule
substitute sheet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016336351A
Other languages
English (en)
Inventor
Gabriela Chiosis
Erica M. Gomes-Dagama
John KOREN
Anna Rodina
Liza SHRESTHA
Tony Taldone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of AU2016336351A1 publication Critical patent/AU2016336351A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2016336351A 2015-10-05 2016-10-05 Rational combination therapy for the treatment of cancer Abandoned AU2016336351A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562237470P 2015-10-05 2015-10-05
US62/237,470 2015-10-05
PCT/US2016/055594 WO2017062520A1 (en) 2015-10-05 2016-10-05 Rational combination therapy for the treatment of cancer

Publications (1)

Publication Number Publication Date
AU2016336351A1 true AU2016336351A1 (en) 2018-05-10

Family

ID=57145064

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016336351A Abandoned AU2016336351A1 (en) 2015-10-05 2016-10-05 Rational combination therapy for the treatment of cancer

Country Status (14)

Country Link
US (1) US20180280397A1 (https=)
EP (1) EP3359196B1 (https=)
JP (1) JP7132848B2 (https=)
KR (1) KR20180058824A (https=)
CN (1) CN108472376A (https=)
AU (1) AU2016336351A1 (https=)
BR (1) BR112018006572A2 (https=)
CA (1) CA3000851A1 (https=)
EA (1) EA201890623A1 (https=)
IL (1) IL258494A (https=)
MA (1) MA47474A (https=)
MX (1) MX2018004112A (https=)
TW (1) TW201722422A (https=)
WO (1) WO2017062520A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015138039A1 (en) 2013-12-23 2015-09-17 Memorial Sloan-Kettering Cancer Center Methods and reagents for radiolabeling
CN110090303B (zh) * 2019-05-07 2022-09-16 浙江大学 阿片受体激动剂在制造用于治疗恶性肿瘤的药物中的用途
CN112641949A (zh) * 2021-01-11 2021-04-13 深圳市人民医院(深圳市呼吸疾病研究所) 一种含有pi3k抑制剂的药物组合物及其应用
US20240371465A1 (en) * 2023-05-02 2024-11-07 National Central University Method, system, and computer readable medium for post-translational modifications detection
CN116813622B (zh) * 2023-05-19 2026-02-03 中国科学院基础医学与肿瘤研究所(筹) 一种基于分子伴侣hsp90介导的靶向降解gpx4的嵌合体及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002228772B2 (en) 2000-11-02 2005-12-08 Sloan Kettering Institute For Cancer Research Methods for enhancing the efficacy of cytotoxic agents through the use of HSP90 inhibitors
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
WO2008005937A2 (en) 2006-06-30 2008-01-10 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibiton of hsp90
NZ713361A (en) 2009-08-17 2017-06-30 Memorial Sloan Kettering Cancer Center Heat shock protein binding compounds, compositions, and methods for making and using same
JP5941407B2 (ja) 2009-10-07 2016-06-29 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Ｈｓｐ９０阻害剤
CN103596955B (zh) 2011-04-05 2016-11-16 索隆-基特林癌症研究协会 Hsp90抑制剂
JP6266506B2 (ja) 2011-04-05 2018-01-24 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Ｈｓｐ９０阻害物質
EA201490230A1 (ru) 2011-07-08 2014-06-30 Слоан-Кеттеринг Инститьют Фор Кэнсер Рисерч Применение меченых ингибиторов hsp90
SG11201601542SA (en) 2013-08-16 2016-04-28 Sloan Kettering Inst Cancer Selective grp94 inhibitors and uses thereof
JP6607870B2 (ja) 2014-05-13 2019-11-20 メモリアル スローン ケタリング キャンサー センター Ｈｓｐ７０モジュレーターならびにその作製および使用方法

Also Published As

Publication number Publication date
WO2017062520A1 (en) 2017-04-13
EA201890623A1 (ru) 2018-09-28
EP3359196B1 (en) 2022-03-16
US20180280397A1 (en) 2018-10-04
CA3000851A1 (en) 2017-04-13
TW201722422A (zh) 2017-07-01
JP7132848B2 (ja) 2022-09-07
MX2018004112A (es) 2018-06-20
JP2018537519A (ja) 2018-12-20
EP3359196A1 (en) 2018-08-15
MA47474A (fr) 2019-12-25
IL258494A (en) 2018-05-31
KR20180058824A (ko) 2018-06-01
CN108472376A (zh) 2018-08-31
BR112018006572A2 (pt) 2018-10-09

Similar Documents

Publication Publication Date Title
Luo et al. Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer
US20240082218A1 (en) Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor for the treatment of cancers
US20240366567A1 (en) Pharmaceutical combinations comprising a kras g12c inhibitor and uses thereof for the treatment of cancers
Abdul Razak et al. First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors
Yang et al. Nrf2 inhibitor, brusatol in combination with trastuzumab exerts synergistic antitumor activity in HER2‐positive cancers by inhibiting Nrf2/HO‐1 and HER2‐AKT/ERK1/2 pathways
Jhaveri et al. A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors
Michmerhuizen et al. PARP1 inhibition radiosensitizes models of inflammatory breast cancer to ionizing radiation
US20230256110A1 (en) Combination of antibody-drug conjugate and atm inhibitor
IL299368A (en) A combination of an antibody-drug conjugate and an ATR inhibitor
EP3359196B1 (en) Rational combination therapy for the treatment of cancer
Mortazavi et al. A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors
Lemjabbar-Alaoui et al. AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers
WO2016130581A2 (en) Combination cancer therapy
Zhou et al. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer
Squillace et al. Antitumor activity of ridaforolimus and potential cell-cycle determinants of sensitivity in sarcoma and endometrial cancer models
EP3962945A1 (en) Rank pathway inhibitors in combination with cdk inhibitors
Feng et al. Combined effects of suberoylanilide hydroxamic acid and cisplatin on radiation sensitivity and cancer cell invasion in non–small cell lung cancer
Li et al. A low-molecular-weight compound exerts anticancer activity against breast and lung cancers by disrupting EGFR/Eps8 complex formation
Wang et al. A novel proteotoxic combination therapy for EGFR+ and HER2+ cancers
Ramirez et al. Pemetrexed acts as an antimyeloma agent by provoking cell cycle blockade and apoptosis
Cao et al. A ligand-based and enediyne-energized bispecific fusion protein targeting epidermal growth factor receptor and insulin-like growth factor-1 receptor shows potent antitumor efficacy against esophageal cancer
Lee et al. A pilot study for the early assessment of the effects of BMS-754807 plus gefitinib in an H292 tumor model by [18F] fluorothymidine-positron emission tomography
HK1259690B (en) Rational combination therapy for the treatment of cancer
HK1259690A1 (en) Rational combination therapy for the treatment of cancer
BR112015013196A2 (en) combinations of a pi3k / akt inhibitor compound with a her3 / egfr inhibitor compound and methods of use

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted